Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study).

IF 3.8 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2025-05-17 DOI:10.1007/s13300-025-01748-1

Viswanathan Mohan, Shashank Joshi, Saket Kant, Altamash Shaikh, L Sreenivasa Murthy, Banshi Saboo, Parminder Singh, Aravind R Sosale, Debmalya Sanyal, G Shanmugasundar, Santosh Kumar Singh, A K Pancholia, Sunetra Mondal, Rishi George, Ashok Jaiswal, Kunal Jhaveri

{"title":"Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study).","authors":"Viswanathan Mohan, Shashank Joshi, Saket Kant, Altamash Shaikh, L Sreenivasa Murthy, Banshi Saboo, Parminder Singh, Aravind R Sosale, Debmalya Sanyal, G Shanmugasundar, Santosh Kumar Singh, A K Pancholia, Sunetra Mondal, Rishi George, Ashok Jaiswal, Kunal Jhaveri","doi":"10.1007/s13300-025-01748-1","DOIUrl":null,"url":null,"abstract":"Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern. MASLD is strongly linked to obesity, sedentary lifestyles, and metabolic syndrome. In India, the prevalence of MASLD exhibits regional variations because of genetic, dietary, and socioeconomic factors. Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) are standardized non-invasive tools for assessing fibrosis and steatosis in MASLD. This study aimed to determine the prevalence and severity of MASLD across different Indian regions and examine regional disparities in MASLD burden.Methods: This retrospective, multicenter, cross-sectional study analyzed the data of 13,750 adults from 105 diabetes and endocrine clinics across six geographic zones in India between May 2023 and February 2024. Participants underwent LSM and CAP assessment using FibroScan™. Based on LSM, liver fibrosis was categorized as F0-F1 (2-7 kPa), F2 (7-10 kPa), F3 (10-14 kPa), and F4 (≥ 14 kPa). Based on CAP, MASLD was classified as mild (238-260 dB/m), moderate (261-292 dB/m), and severe (≥ 293 dB/m).Results: The prevalence of MASLD was 68.2% (CAP ≥ 238 dB/m), and the prevalence of fibrosis was 33.7% (LSM ≥ 7 kPa). The highest MASLD burden was observed in North India (73.3%), particularly in Uttarakhand (80.0%). Severe fibrosis (F4) was highly prevalent in Kerala (20.0%), whereas severe steatosis (S3) was highly prevalent in Jammu and Kashmir (50.3%). The prevalence of MASLD was significantly associated with regional variations (P < 0.001) but not with age.Conclusion: This study highlights significant regional disparities in MASLD burden. The high burden in North India calls for region-specific public health interventions, standardized screening, and preventive strategies.","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-025-01748-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern. MASLD is strongly linked to obesity, sedentary lifestyles, and metabolic syndrome. In India, the prevalence of MASLD exhibits regional variations because of genetic, dietary, and socioeconomic factors. Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) are standardized non-invasive tools for assessing fibrosis and steatosis in MASLD. This study aimed to determine the prevalence and severity of MASLD across different Indian regions and examine regional disparities in MASLD burden.

Methods: This retrospective, multicenter, cross-sectional study analyzed the data of 13,750 adults from 105 diabetes and endocrine clinics across six geographic zones in India between May 2023 and February 2024. Participants underwent LSM and CAP assessment using FibroScan™. Based on LSM, liver fibrosis was categorized as F0-F1 (2-7 kPa), F2 (7-10 kPa), F3 (10-14 kPa), and F4 (≥ 14 kPa). Based on CAP, MASLD was classified as mild (238-260 dB/m), moderate (261-292 dB/m), and severe (≥ 293 dB/m).

Results: The prevalence of MASLD was 68.2% (CAP ≥ 238 dB/m), and the prevalence of fibrosis was 33.7% (LSM ≥ 7 kPa). The highest MASLD burden was observed in North India (73.3%), particularly in Uttarakhand (80.0%). Severe fibrosis (F4) was highly prevalent in Kerala (20.0%), whereas severe steatosis (S3) was highly prevalent in Jammu and Kashmir (50.3%). The prevalence of MASLD was significantly associated with regional variations (P < 0.001) but not with age.

Conclusion: This study highlights significant regional disparities in MASLD burden. The high burden in North India calls for region-specific public health interventions, standardized screening, and preventive strategies.

查看原文本刊更多论文

代谢功能障碍相关脂肪变性肝病的患病率：绘制不同印度人群的地图（MAP研究）。

代谢功能障碍相关的脂肪变性肝病（MASLD）是一个日益增长的全球健康问题。MASLD与肥胖、久坐不动的生活方式和代谢综合征密切相关。在印度，由于遗传、饮食和社会经济因素，MASLD的患病率表现出区域差异。肝硬度测量（LSM）和控制衰减参数（CAP）是评估MASLD纤维化和脂肪变性的标准化非侵入性工具。本研究旨在确定MASLD在印度不同地区的患病率和严重程度，并检查MASLD负担的地区差异。方法：这项回顾性、多中心、横断面研究分析了2023年5月至2024年2月期间印度六个地理区域105家糖尿病和内分泌诊所的13750名成年人的数据。参与者使用FibroScan™进行LSM和CAP评估。肝纤维化按LSM分为F0-F1 （2-7 kPa）、F2 （7-10 kPa）、F3 （10-14 kPa）、F4（≥14 kPa）。根据CAP， MASLD分为轻度（238 ~ 260 dB/m）、中度（261 ~ 292 dB/m）和重度（≥293 dB/m）。结果：MASLD患病率为68.2% (CAP≥238 dB/m)，纤维化患病率为33.7% （LSM≥7 kPa）。印度北部的MASLD负担最高（73.3%），特别是北阿坎德邦（80.0%）。严重纤维化（F4）在喀拉拉邦非常普遍（20.0%），而严重脂肪变性（S3）在查谟和克什米尔非常普遍（50.3%）。结论：本研究强调了MASLD负担的显著地区差异。印度北部的高负担要求采取针对特定区域的公共卫生干预措施、标准化筛查和预防战略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.